Variant Bio Launches Inference, the World's First Agentic AI Genomic Drug Discovery Platform

Variant Bio, a genomics-driven AI drug discovery company, today announced the launch of Inference, the world's first agentic genomic drug dis ...
EurekAlert!

Introducing NorthPole: a brain-inspired chip design that enables low-power AI inference

Researchers present NorthPole – a brain-inspired chip architecture that blends computation with memory to process data efficiently at low-energy costs. Since its inception, computing has been ...

DGrid Launches First Web3 Decentralized Gateway Aggregation for AI Inference

DGrid, a next-generation decentralized AI infrastructure, today announced its official launch in 2026, introducing a pioneering solution that combines decentralized architecture with advanced AI ...
Morningstar

Variant Bio Launches Inference, the World's First Agentic AI Genomic Drug Discovery Platform

SEATTLE, Jan. 6, 2026 /PRNewswire/ -- Variant Bio, a genomics-driven AI drug discovery company, today announced the launch of Inference, the world's first agentic genomic drug discovery platform.